Source: Web Search Publisher: Stallion laboratories Pvt. Ltd., C-1B, 305/2,3,4 & 5, GIDC, Kerala (Bavla) Dist: Ahmedabad-382220, Gujarat, India
Hypersensitivity to Dexrabeprazole Sodium.
Symptomatic response to therapy does not preclude the presence of gastric malignancy.
No clinically significant interactions with drugs metabolized by CYP450 system. An interaction with compounds (e.g Ketoconazole) which are dependent on gastric pH for absorption may occour due to the magnitude of acid suppression.
May reduce absorption of ketoconazole and itraconazole. May prolong the elimination of diazepam, phenytoin and warfarin.
Studies in animals have shown no risk to the fetus, however there are no sufficient studies in humans. Patients should follow the advice of the doctor regarding its use.
Safer: Drug has been studied in few breastfeeding women and the evidence shows that there is no increase in side effects in the infants, or the possibility of harm to the breastfed infants is expected to be rare. Patients should follow the advice of the doctor regarding its use.
There are no data to suggest that Dexrabeprazole affects the ability to drive or use machines.
Headache, diarrhea, nervousness, abdominal pain, pharyngitis, rash and dry mouth.
Not applicable.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
